NIVF — NewGenIvf Group Limited

Is NIVF overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Strong Oversold As of November 17, 2026

NewGenIvf Group Limited (NIVF) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $0.20. The rating moved from Oversold to Strong Oversold on October 31, 2026.

See all oversold Healthcare stocks →

AI analysis

NewGenIvf Group Limited (NIVF) operates in a secularly growing fertility market with exposure to elective and outpatient care trends. Limited public financial disclosure and small-cap liquidity create meaningful information and execution risk, while successful local clinic scaling, partnerships and service expansion could drive incremental revenue. Near-term sentiment is tied to operational updates and any signs of margin improvement or capital-strengthening actions. Absent clearer filings or visible cash-flow improvement, the profile is one of both opportunity and elevated risk.

Key factors

  • Exposure to growing long-term demand for fertility and assisted-reproduction services as demographics and delayed childbearing support secular growth
  • Business model tied to elective, cash-pay and insured procedures which can show resilience but are cyclical with consumer confidence
  • Potential to expand outpatient, telehealth and home-based fertility support consistent with healthcare shift to outpatient modalities
  • Small-cap status with limited public disclosure and analyst coverage increases information asymmetry and event-driven upside if positive operational updates occur
  • Operational execution and local clinic footprint are differentiators if management scales referrals, lab capabilities and partnerships with OB/GYN networks
  • Current market tone is cautiously optimistic for growth healthcare names, which may provide modest near-term demand support

Risks

  • Thin liquidity and low float can produce outsized volatility and make exits or capital raises expensive for investors
  • High likelihood of future dilution if the company needs to raise capital to fund operations, technology or lab expansions
  • Regulatory and reimbursement risk: changes in insurance coverage or fertility-related policies could materially impact revenue
  • Intense competition from larger, better-funded clinic chains and vertically integrated fertility platforms
  • Lack of recent EDGAR/filing transparency and limited third-party research increases uncertainty around financial health
  • Macroeconomic weakness or declines in discretionary consumer spending could reduce procedure volumes

See today's live rating, score and targets

Members see the live hourly rating for NIVF — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.